We are live on ! Find out more
GNMX

Aevi Genomic Medicine Inc
GNMX

Delisted

GNMX was delisted on the 3rd of February, 2020.

Back to rankings

76 hedge funds and large institutions have $88.1M invested in Aevi Genomic Medicine Inc in 2016 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 25 increasing their positions, 15 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,853% more call options, than puts

Call options by funds: $6.58M | Put options by funds: $337K

133% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 6

67% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 15

12% more funds holding

Funds holding: 68 → 76 (+8)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

3% less capital invested

Capital invested by funds: $91.2M → $88.1M (-$3.13M)

Holders
76
Holders Change
+8
Holders Change %
+11.76%
% of All Funds
1.9%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
14
Increased
25
Reduced
15
Closed
6
Calls
$6.58M
Puts
$337K
Net Calls
+$6.24M
Net Calls Change
+$5.86M

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$1.91M
2
BFA
BlackRock Fund Advisors
California
+$745K
3
Morgan Stanley
Morgan Stanley
New York
+$390K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$386K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$362K

Top Sellers

Rank Fund Capital Flow
1
OM
Opaleye Management
Massachusetts
-$1.58M
2
QF
QVT Financial
New York
-$688K
3
SS
Sunbelt Securities
Texas
-$223K
4
TD Asset Management
TD Asset Management
Ontario, Canada
-$203K
5
BFM
Boothbay Fund Management
New York
-$84K
Name Holding Trade Value Shares
Change 		Change in
Stake
BC
26
Birchview Capital
Vermont
$249K +$73.7K +14,000 +41%
OAM
27
Oxford Asset Management
United Kingdom
$249K +$193K +36,728 +326%
Charles Schwab
28
Charles Schwab
California
$228K – – –
TC
29
TFS Capital
Pennsylvania
$226K +$230K +43,622 New
LPL Financial
30
LPL Financial
California
$213K -$7.77K -1,477 -4%
TA
31
Teachers Advisors
New York
$204K – – –
NCMW
32
Northern Capital Management (Wisconsin)
Wisconsin
$186K – – –
CD
33
Carl Domino
Florida
$172K – – –
Squarepoint
34
Squarepoint
New York
$161K +$164K +31,152 New
Citadel Advisors
35
Citadel Advisors
Florida
$145K +$148K +28,081 New
RhumbLine Advisers
36
RhumbLine Advisers
Massachusetts
$139K +$11K +2,093 +8%
JP Morgan Chase
37
JP Morgan Chase
New York
$129K +$131K +24,863 New
SQA
38
Simon Quick Advisors
New Jersey
$126K +$128K +24,390 New
Wells Fargo
39
Wells Fargo
California
$119K +$51.1K +9,709 +73%
Manulife (Manufacturers Life Insurance)
40
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$111K +$38.2K +7,257 +51%
WPC
41
White Pine Capital
Minnesota
$104K – – –
Goldman Sachs
42
Goldman Sachs
New York
$94K -$27.1K -5,155 -22%
NFA
43
Nationwide Fund Advisors
Ohio
$90K -$17.1K -3,255 -16%
BA
44
BlackRock Advisors
Delaware
$86K +$5.4K +1,027 +7%
New York State Common Retirement Fund
45
New York State Common Retirement Fund
New York
$80K – – –
CDH
46
Charles D. Hyman
$78K – – –
VanEck Associates
47
VanEck Associates
New York
$75K -$6.83K -1,299 -8%
Deutsche Bank
48
Deutsche Bank
Germany
$75K +$53K +10,076 +221%
AIG
49
American International Group
New York
$73K -$195 -37 -0.3%
CS
50
Credit Suisse
Switzerland
$71K +$18.2K +3,461 +34%
1
2
3 4

GNMX Hedge Fund Activity: Q4 2016 in Review

76 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Aevi Genomic Medicine Inc (GNMX) for Q4 2016, worth a combined $88.1M — down 3.4% from $91.2M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new GNMX positions and 6 closed out — a net gain of 8 holders — while 25 added to existing stakes and 15 trimmed.

The largest buyer was Millennium Management, opening a new position worth an estimated $1.91M. The largest seller was Opaleye Management, cutting an estimated $1.58M.

  • 76 institutional investors held Aevi Genomic Medicine Inc (GNMX) as of Q4 2016, up from 68 in Q3 2016.
  • Funds reported $88.1M of Aevi Genomic Medicine Inc stock for Q4 2016, down 3.4% quarter-over-quarter.
  • 14 funds opened new Aevi Genomic Medicine Inc positions in Q4 2016 and 6 closed out, a net change of +8 holders.
  • The largest Aevi Genomic Medicine Inc buyer in Q4 2016 was Millennium Management, an estimated $1.91M added.
  • The largest Aevi Genomic Medicine Inc seller in Q4 2016 was Opaleye Management, an estimated $1.58M sold.

Based on aggregated 13F filings for Q4 2016.